- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 05.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.05. | Psyence Biomedical Ltd.: Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing | 1 | GlobeNewswire (USA) | ||
| 23.04. | Psyence Biomedical doses first patient in psilocybin cancer trial | 2 | Investing.com | ||
| 23.04. | Psyence Biomedical startet Phase-IIb-Studie mit Psilocybin bei Krebspatienten | 2 | Investing.com Deutsch | ||
| 23.04. | Psyence Biomedical Ltd.: Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder | 258 | GlobeNewswire (Europe) | NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company developing nature-derived psychedelic... ► Artikel lesen | |
| 20.04. | Psyence Biomedical Ltd.: Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source | 18 | GlobeNewswire (USA) | ||
| 17.04. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 17.04. | Psyence Biomedical Stock Surges 42% On Growing Interest In Ibogaine Research | 3 | RTTNews | ||
| 17.04. | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | 624 | GlobeNewswire (Europe) | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| 17.04. | Morning Market Movers: Psyence Biomedical, WeShop, Julong Holding, Lifezone Metals See Big Swings | 746 | AFX News | BEIJING (dpa-AFX) - At 7:55 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 08.04. | Psyence Biomedical expands Australian clinical sites to five | 2 | Investing.com | ||
| 08.04. | Psyence Biomedical baut Studiennetzwerk in Australien aus | 3 | Investing.com Deutsch | ||
| 08.04. | Psyence Biomedical Ltd.: Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities | 1 | GlobeNewswire (USA) | ||
| 11.03. | Psyence Biomedical Ltd.: Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone | 1 | GlobeNewswire (USA) | ||
| 03.03. | Psyence Biomedical Ltd.: Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | 368 | GlobeNewswire (Europe) | NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 02.03. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment | 473 | GlobeNewswire (Europe) | NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen | |
| 17.02. | Psyence Biomedical Ltd.: Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders | 253 | GlobeNewswire (Europe) | NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,860 | +0,26 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| PALATIN TECHNOLOGIES | 10,610 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,268 | +3,93 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,359 | -0,83 % | NurExone stärkt globalen Patentschutz für seine Exosomen-Plattform | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,269 | -0,31 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,900 | -0,99 % | RedHill Biopharma closes $6 million private placement | ||
| ONCO-INNOVATIONS | 0,450 | +1,12 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| NOVOCURE | 12,750 | -1,73 % | Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start... ► Artikel lesen | |
| PHARMING | 1,161 | +1,13 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,800 | +1,15 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| REVOLUTION MEDICINES | 150,00 | +0,30 % | Das geheime Verfahren das Krebszellen sterben lässt: Was Revolution Medicines und Merck & Co. von Vidac Pharma lernen müssen | Hier kann man ohne Übertreibung von einer Patent-Superklippe sprechen: Satte 236 Mrd. USD drohende jährliche Umsatzverluste zwingen die biopharmazeutische Industrie dazu, neue Wege zu gehen. Pharma-Riesen... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,840 | -1,39 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| PALISADE BIO | 1,925 | +0,26 % | Palisade Bio, Inc.: Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors | Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,922 | 0,00 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches | SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from... ► Artikel lesen | |
| OMEROS | 9,420 | +1,07 % | OMEROS CORP - 8-K, Current Report |
PSYENCE BIOMEDICAL LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,030 (+1,09 %) liegt der Kurs bei 2,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.